Compare BridgeBio Pharma Inc (BBIO) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Funko Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Funko Inc trades at $6.23 (market cap $346.61M). The key difference: BridgeBio Pharma Inc is far larger — about 47.9× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FNKO | |
|---|---|---|
Market Cap | $16.61B | $346.61M |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $6.35 |
52-Week Low | $47.29 | $2.65 |
Enterprise Value | $18.16B | $567.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Funko (FNKO) trades at $5.88, up 11.36% today, with strong technical momentum showing bullish signals across moving averages and oscillators. The company reported improved Q2 2026 results with net sales up 7% to $207.7 million and raised adjusted EBITDA guidance, though full-year 2025 showed a net loss of $67.36 million on $908.21 million revenue. Analyst sentiment is mixed with 42.9% buy ratings, while institutional ownership remains stable.
The outlook suggests potential recovery with recent earnings beats and strategic hires, but risks include persistent negative margins, high debt levels at 32.89% debt-to-asset ratio, and competitive pressures in the collectibles market. Valuation appears reasonable with P/S of 0.35 and EV/EBITDA of 6.41, offering upside if turnaround continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
